



Att. Docket No.: REG 720

1632
#6
1/23/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

USSN: 10/018,761

Applicant: Glass, et al.

Date Filed: June 10, 2002

For : Methods of Inhibiting Muscle Atrophy

FIRST CLASS MAIL CERTIFICATE

I hereby certify that this document is being deposited with the United States Postal Service on this date as first class mail addressed to: Commissioner for Patents, United States Patent and Trademark Office, Washington, D.C. 20231.

Bernadette B. Fahey
Bernadette B. Fahey

January 15, 2003
Date

RECEIVED

JAN 22 2003

TECH CENTER 1600/2901

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§ 1.56 and 1.97**

January 15, 2003

Assistant Comm. Patent and Trademarks
Washington, D.C. 20231

Dear Sir:

In compliance with the applicant's duty to submit information material to patentability of the above-referenced case, Applicants herein submit the following Information Disclosure Statement with the accompanying PTO Form 1449 and copies of references listed therein. The PTO is kindly requested to make of record those references which may be pertinent to the examination of the above-referenced application.

This Information Disclosure Statement is being filed:

- [X] (b) Within three months of the filing date of the above referenced application; within three months of the entry of an international application into the national phase; before the mailing date of a first Office action on the merits; or before the mailing of a first Office action after the filing of a request for continued examination under § 1.114. Accordingly, no fee is required for the submission.

or

☐ (c) After (b) above, but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or any action that otherwise closes prosecution in the application. Accordingly, the undersigned certifies as follows:

☐ (e)(1) Each item of information contained in this IDS was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the date of the filing of this IDS; or

☐ (e)(2) No item of information contained in this IDS was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the person signing the certification after making reasonably inquiry, no item of information contain in the IDS was known to any individual designated in § 1.56(c) more than three months prior to the filing of this IDS;

or

☐ This IDS is accompanied by the fee set forth in 37 CFR § 1.17(p);

or

☐ (d) After (c) above, but on or before payment of the issue fee and the undersigned certifies as follows:


☐ (e)(1) Each item of information contained in this IDS was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the date of the filing of this IDS; or

☐ (e)(2) No item of information contained in this IDS was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the person signing the certification after making reasonably inquiry, no item of information contain in the IDS was known to any individual designated in § 1.56(c) more than three months prior to the filing of this IDS;

and

[] This IDS is accompanied by the fee set forth in 37 CFR § 1.17(p).

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Laura J. Fischer", written over a horizontal line.

Laura J. Fischer

Reg. No. 50,420

Attorney for Applicants

Regeneron Pharmaceuticals, Inc.

777 Old Saw Mill River Road

Tarrytown, New York 10591

(914) 345-7400



FORM PTO-1449

Att. Docket No.: REG 720

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

USSN : 10/018,761

Applicant: Glass, et al.

Date Filed: June 10, 2002

Title: Methods of Inhibiting Muscle Atrophy

Examiner: Not Yet Known

Group Art Unit: Not Yet Known

January 15, 2003

RECEIVED

JAN 22 2003

U.S. PATENT DOCUMENTS

TECH CENTER 1600/290C

Examiner Initials	Patent Number	Issue Date	Publication Number	Publication Date	Name
----------------------	------------------	---------------	-----------------------	---------------------	------

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Country	Class/ Subclass	Translation Yes No
----------------------	--------------------	------	---------	--------------------	-----------------------

OTHER DOCUMENTS
(Including Author, Title, Date, Pertinent Pages, etc.)

Boulton TG, et al. (1991) Cell 65:663-75

Crews CM, et al. (1992) Science 258:478-80;

Dudley D, et al. Proc.Natl. Acad. Sci. (1995) 92:7686.

Heidecker, et al. (1990) Mol. Cell. Biol. 10:2503;

Hunter J, et al. J Biol Chem. 1995 Sep 29;270(39):23173-8;

Morrison, et al. (1997) Curr. Opin. Cell Biol. 9:174;

Samuels, et al. (1993) Mol. Cell. Biol. 13:6241;

_____ Taparowsky E, et al. (1982) Nature 300:762-5;
_____ Cancer Chemother Pharmacol. (1999) 43(1):50-8;
_____ Trends Genet 1999 Apr;15(4):145-9.

RECEIVED

JAN 22 2003

TECH CENTER 1600/2900

EXAMINER
CONSIDERED

DATE

EXAMINER:

Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Respectfully submitted,

By:



Laura J. Fischer
Reg. No. 50,420
Attorney for Applicants
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591
(914) 345-7400